Congress Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Congress Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-52,929	Closed	-$786K	–	390
2017 Q2	$786K	Buy	52,929 +9,496	+22%	+$132K	0.01%	215
2017 Q1	$521K	Buy	43,433 +16,655	+62%	+$211K	0.01%	220
2016 Q4	$370K	Buy	26,778 +11,563	+76%	+$160K	0.01%	236
2016 Q3	$204K	Buy	+15,215	New	+$184K	﹤0.01%	246

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Congress Asset Management's LFCR Position: Q3 2017 in Review

Congress Asset Management sold out of Lifecore Biomedical (LFCR) in Q3 2017, closing a stake of 52,929 shares — an estimated $786K sold.

Congress Asset Management first reported a position in LFCR in Q3 2016 and held it in 4 quarters. The position peaked at $786K in Q2 2017. 95 funds tracked by Wall St. Rank hold LFCR as of Q3 2017.

Congress Asset Management reported no remaining Lifecore Biomedical position as of Q3 2017 after selling out during the quarter.
Congress Asset Management sold 52,929 Lifecore Biomedical shares in Q3 2017, an estimated $786K.
Congress Asset Management first reported a position in Lifecore Biomedical in Q3 2016 and held it in 4 quarters.
Congress Asset Management's Lifecore Biomedical position peaked at $786K in Q2 2017.
95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2017.

Based on Congress Asset Management's 13F filing for Q3 2017, filed 17 Oct 2017.